Impact of MetaCalm on Stress of Healthy People With Acute Stress

Evaluation of MetaCalm at Two Dose Levels in Healthy Adults With Acute Stress: An Open-Label, Non-Randomized Clinical Study

This Open-Label, Non-Randomized Clinical Study involving 280 participants who will undergo a total participation of 6 hours.

The trial begins with a screening process to assess eligibility for the study. Participants will then receive 2 or 4 MetaCalm chewable tablets, followed by a 6-hour phase during which they will be asked to complete several questionnaires at different times after taking the tablets.

Inclusion Criteria:

• Providing written informed consent
• Males and females of at least 18 years old
• Obtaining a reference score of ≥ 30 on the STAI questionnaire (State-Trait Anxiety Inventory, short version, 10-item scale)

Exclusion Criteria:

• Being on anxiolytic and beta blocker treatment
• Individuals who use illicit or recreational drugs
• Having consumed adaptogen plants in one week prior to enrollment
• Participating in another clinical trial
• Patients diagnosed with cancer
• Allergic to any of the ingredients in this product
• Obtaining a reference score of less than 30 on the STAI questionnaire (State-Trait Anxiety Inventory, short version, 10-item scale)